UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

The Consortium of Metabolomics Studies (COMETS): Metabolomics in 47 Prospective Cohort Studies

Yu, B; Zanetti, KA; Temprosa, M; Albanes, D; Appel, N; Barrera, CB; Ben-Shlomo, Y; ... Moore, SC; + view all (2019) The Consortium of Metabolomics Studies (COMETS): Metabolomics in 47 Prospective Cohort Studies. American Journal of Epidemiology , 188 (6) pp. 991-1012. 10.1093/aje/kwz028.

[img] Spreadsheet
Web Table 3.xlsx - Accepted version
Access restricted to UCL open access staff until 20 February 2020.

Download (151kB)
[img] Slideshow
00921-2018 Moore Figure 1.pptx - Accepted version
Access restricted to UCL open access staff until 20 February 2020.

Download (536kB)
[img] Image
00921-2018 Moore Figure 2.pdf - Accepted version
Access restricted to UCL open access staff until 20 February 2020.

Download (9kB)
[img] Image
00921-2018 Moore Figure 2.ps - Accepted version
Access restricted to UCL open access staff until 20 February 2020.

Download (242kB)
[img] Text
Tillin The Consortium of Metabolomics Studies copy edited.pdf - Accepted version
Access restricted to UCL open access staff until 20 February 2020.

Download (1MB)
[img] Text
Tillin Supplementary materials.pdf - Accepted version
Access restricted to UCL open access staff until 20 February 2020.

Download (598kB)

Abstract

The Consortium of Metabolomics Studies (COMETS) was established in 2014 to facilitate large-scale collaborative research on the human metabolome and its relationship with disease etiology, diagnosis, and prognosis. COMETS comprises 47 cohorts from Asia, Europe, North America, and South America that together include more than 136,000 participants with blood metabolomics data on samples collected from 1985 to 2017. Metabolomics data were provided by 17 different platforms, with the most frequently used labs being Metabolon, Inc. (14 cohorts), the Broad Institute (15 cohorts), and Nightingale Health (11 cohorts). Participants have been followed for a median of 23 years for health outcomes including death, cancer, cardiovascular disease, diabetes, and others; many of the studies are ongoing. Available exposure-related data include common clinical measurements and behavioral factors, as well as genome-wide genotype data. Two feasibility studies were conducted to evaluate the comparability of metabolomics platforms used by COMETS cohorts. The first study showed that the overlap between any 2 different laboratories ranged from 6 to 121 metabolites at 5 leading laboratories. The second study showed that the median Spearman correlation comparing 111 overlapping metabolites captured by Metabolon and the Broad Institute was 0.79 (interquartile range, 0.56-0.89).

Type: Article
Title: The Consortium of Metabolomics Studies (COMETS): Metabolomics in 47 Prospective Cohort Studies
Location: United States
DOI: 10.1093/aje/kwz028
Publisher version: https://doi.org/10.1093/aje/kwz028
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: Cancer, cohort, diabetes, genetics, heart disease, metabolomics, prospective
UCL classification: UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Pop Health Sciences > Institute of Cardiovascular Science
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Pop Health Sciences > Institute of Epidemiology and Health
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Pop Health Sciences > Institute of Epidemiology and Health > Epidemiology and Public Health
URI: https://discovery.ucl.ac.uk/id/eprint/10077421
Downloads since deposit
6Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item